Clozapine: Is now the time for more clinicians to adopt this orphan?

CNS Spectrums

Volumn 19, Issue 4, 2014, Pages 279-281

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TREATMENT INDICATION; ADVERSE OUTCOME; AGRANULOCYTOSIS; CONSTIPATION; DIABETES MELLITUS; DIFFUSE LEWY BODY DISEASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHILIA; HYPERSALIVATION; ILEUS; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PARKINSON DISEASE; QT PROLONGATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; TACHYCARDIA; TREATMENT RESPONSE; CHEMICALLY INDUCED; PRACTICE GUIDELINE; WEIGHT GAIN;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONSTIPATION; DIABETES MELLITUS; EOSINOPHILIA; HUMANS; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; SCHIZOPHRENIA; SIALORRHEA; TACHYCARDIA; WEIGHT GAIN;

EID: 84906568188     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000418     Document Type: Article

References (23)

1. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163(4): 600-610. (Pubitemid 44464569)
2. Hermes E, Rosenheck R. Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. J Psychopharmacol. 2012; 26(9): 1194-1200.
3. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010; 24(7): 965-971.
4. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012; 6(3): 134-144.
5. Stahl SM. Stahls Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
6. Stahl SM, Morrissette DA, Citrome L, et al. "Meta-guidelines" for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150-162.
7. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry. 2003; 60(1): 82-91.
8. Stahl SM. The Prescribers Guide: Stahls Essential Psychopharmacology, 5th ed. Cambridge, UK: Cambridge University Press; 2014.
9. Fazel S, Zetterqvist J, Larsson H, Langstrom N, Lichtenstein P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet. In press. DOI: 10.1016/ S0140-6736(14)60379-2.
10. Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapines antiaggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351-1371.
11. KrakowskiMK, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006; 63(6): 622-629. (Pubitemid 43848293)
12. Hotham JE, Simpson PJD, Brooman-White RS, et al. Augmentation of clozapine with amizulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high security hospital. CNS Spectr. In press. DOI: 10.1017/S1092852913000874.
13. Volavka J, Czoborb P, Citrome LL, Van Dorn RA. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. In press. DOI: 10.1017/S1092852913000849.
14. Brown D, Larkin F, Sengupta S, et al. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. In press. DOI: 10.1017/ S1092852914000157.
15. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009; 374(9690): 620-627.
16. Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012; 73(10): 1307-1314.
17. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013; 74(6): 603-613.
18. Hsieh MM, Everhard JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007; 146(7): 486-492. (Pubitemid 351650557)
19. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005; 81(959): 545-546. (Pubitemid 41297905)
20. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Bull. 2012; 134(2-3): 180-186.
21. Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebocontrolled crossover study. J Clin Psychiatry. 2009; 70(8): 1114-1119.
22. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012; 38(3): 592-598.
23. Meyer JM, Cummings MA. Lubiprostone for treatment resistant constipation associated with clozapine use. Acta Psychiatr Scand. 2014; 130(1): 71-72.